Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Completed

A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP

A Randomized Study to Compare LMA® Gastro™, a Dual Channel Supraglottic Airway (SGA) Device, to Oxygenation With Standard Nasal Cannula for Endoscopic Retrograde Cholangiopancreatography (ERCP)

Outcome
Results posted; no analysis attached
Phase
No phase (not a drug trial)
Status
Completed
Study type
Interventional
Start
24 February 2021
Ended
4 May 2023
Enrollment
66 participants
Sites
1
Primary outcomes
Number of Participants That Had Desaturation Episodes of SpO2 <90%
Sponsor type
Academic / other
Results posted
6 November 2024
Last update
6 November 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 6 November 2024
Primary outcome
Number of Participants That Had Desaturation Episodes of SpO2 <90%Desaturation <90% - Yes: LMA Gastro: 0 of 26Desaturation <90% - Yes: Standard of Care: 3 of 30Desaturation <90% - No: LMA Gastro: 26 of 26Desaturation <90% - No: Standard of Care: 27 of 30Values: ParticipantsTime frame: The time between Anesthesia Start time and Anesthesia End time, 1.5 hrs in averageNo analysis posted for this outcome (outcome 1)
Participants
LMA Gastro: 33 started, 26 completedStandard of Care: 33 started, 30 completed
Serious adverse events
LMA Gastro: 0 of 26Standard of Care: 0 of 30Participants with at least one serious adverse event, of those at risk, as posted
9 secondary outcomes, the first 8 shown
Incidence of Additional Airway Maneuvers
Yes: LMA Gastro 5/26; Standard of Care 19/30 [Participants] (first of 2 rows)
Incidence of Withdrawal of Duodenoscope From Airway to Facilitate Airway Support
Yes: LMA Gastro 9/26; Standard of Care 10/30 [Participants] (first of 2 rows)
Incidence of Adverse Events
LMA Gastro 24, n=26; Standard of Care 3, n=30 [events]
To Evaluate Times Related to Anesthesia and Procedure
Total Anesthesia Time: LMA Gastro 75.0769 (46 to 152), n=26; Standard of Care 62.8667 (35 to 165), n=30 [mean minutes, Full Range] (first of 2 rows)
To Evaluate Time From Procedure End to Anesthesia End
LMA Gastro 18.5769 (10 to 49), n=26; Standard of Care 11.2 (2 to 22), n=30 [mean minutes, Full Range]
To Describe Heart Rates Within the Two Groups
Heart rate prior to intervention: LMA Gastro 79.8846 (16.7412), n=26; Standard of Care 77.3667 (13.7853), n=30 [mean bpm, Standard Deviation] (first of 2 rows)
To Describe Blood Pressure and End Tidal Carbon Dioxide [CO2] Within the Two Groups
Systolic Blood pressure prior to intervention: LMA Gastro 127.2308 (19.4757), n=26; Standard of Care 137.5714 (28.3097), n=30 [mean mmhg, Standard Deviation] (first of 6 rows)
To Describe Oxygen Saturations Within the Two Groups
Oxygen saturation prior to intervention: LMA Gastro 98.5769 (1.9426), n=26; Standard of Care 99.033 (1.1885), n=30 [mean percentage of saturation, Standard Deviation] (first of 2 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This clinical trial compares the effect of LMA Gastro, a dual channel supraglottic airway (SGA) device, to oxygenation with standard nasal cannula for endoscopic retrograde cholangiopancreatography (ERCP). An ERCP is a combination of imaging scans and endoscopy that helps doctors diagnose and treat conditions of the pancreas and bile ducts that requires general anesthesia or procedural sedation. Anesthesiologists often use SGAs or nasal cannulas to help patients breathe while they are asleep during procedures. An SGA consists of an airway tube that connects to a mask, which is inserted through the mouth and placed at the back of the throat to keep the airway open while patients are under anesthesia or sedation. The nasal cannula is a device that fits in a patient's nostrils and delivers oxygen through a small, flexible tube while they are under anesthesia or sedation. The goal of this trial is to compare the effects of the LMA Gastro to nasal cannula when used to deliver oxygen to patients while they are asleep during their ERCP procedure.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVE: I. To compare the incidence of desaturation (oxygen saturation \[SpO2\] \< 90%) between patients undergoing ERCP with LMA Gastro versus (vs) standard nasal cannula. SECONDARY OBJECTIVES: I. To evaluate the incidence of additional airway maneuvers (jaw thrust/chin lift/placement of oral airway or/nasal trumpet/intubation). II. To evaluate the incidence of withdrawal of duodenoscope from the airway to facilitate airway support. III. To evaluate the incidence of adverse events. IV. To evaluate times related to anesthesia and procedure (defined as "anesthesia start to anesthesia end" and "procedure start to procedure end" respectively). V. To evaluate time from procedure end to anesthesia end. VI. To describe hemodynamics within the two groups (recorded blood pressures, heart rates, oxygen saturations, and end tidal carbon dioxide \[CO2\]). VII. To evaluate anesthesiologist placing the device (training video viewed, number of practice attempts, years of experience). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo ERCP with LMA Gastro. ARM II: Patients undergo ERCP with standard nasal cannula.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Number of Participants That Had Desaturation Episodes of SpO2 <90% [The time between Anesthesia Start time and Anesthesia End time, 1.5 hrs in average]. Count Of Participants, Participants. Desaturation <90% - Yes: LMA Gastro (n=26): 0; Standard of Care (n=30): 3. Desaturation <90% - No: LMA Gastro (n=26): 26; Standard of Care (n=30): 27.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Incidence of Additional Airway Maneuvers [The time between Anesthesia Start time and Anesthesia End time, 1.5 hrs in average]. Count Of Participants, Participants. Yes: LMA Gastro (n=26): 5; Standard of Care (n=30): 19. No: LMA Gastro (n=26): 21; Standard of Care (n=30): 11.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Incidence of Withdrawal of Duodenoscope From Airway to Facilitate Airway Support [The time between Anesthesia Start time and Anesthesia End time]. Count Of Participants, Participants. Yes: LMA Gastro (n=26): 9; Standard of Care (n=30): 10. No: LMA Gastro (n=26): 17; Standard of Care (n=30): 20.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Incidence of Adverse Events [From PACU arrival to PACU discharge, 3 hours in average]. Number, events. LMA Gastro (n=26): 24; Standard of Care (n=30): 3.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

To Evaluate Times Related to Anesthesia and Procedure [From anesthesia start to anesthesia end" and "procedure start to procedure end, up to 165 minutes]. Mean, minutes (Full Range). Total Anesthesia Time: LMA Gastro (n=26): 75.0769 (46 to 152); Standard of Care (n=30): 62.8667 (35 to 165). Total Procedure Time: LMA Gastro (n=26): 32.6154 (3 to 113); Standard of Care (n=30): 45.5333 (13 to 143).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

To Evaluate Time From Procedure End to Anesthesia End [From procedure end and anesthesia end, up to 60 minutes]. Mean, minutes (Full Range). LMA Gastro (n=26): 18.5769 (10 to 49); Standard of Care (n=30): 11.2 (2 to 22).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

To Describe Heart Rates Within the Two Groups [From "anesthesia start" to "anesthesia end", on average 5 hours]. Mean, bpm (Standard Deviation). Heart rate prior to intervention: LMA Gastro (n=26): 79.8846 (16.7412); Standard of Care (n=30): 77.3667 (13.7853). Heart rate post intervention: LMA Gastro (n=26): 77.1154 (15.8501); Standard of Care (n=30): 66.9667 (10.3607).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

To Describe Blood Pressure and End Tidal Carbon Dioxide [CO2] Within the Two Groups [From "anesthesia start" to "anesthesia end", on average 5 hours]. Mean, mmhg (Standard Deviation). Systolic Blood pressure prior to intervention: LMA Gastro (n=26): 127.2308 (19.4757); Standard of Care (n=30): 137.5714 (28.3097). Systolic Blood pressure post intervention: LMA Gastro (n=26): 122.0769 (15.0676); Standard of Care (n=30): 128.2 (23.5231). Diastolic Blood pressure prior to intervention: LMA Gastro (n=26): 78.3462 (10.7664); Standard of Care (n=30): 80.8571 (15.1846). Diastolic Blood pressure post intervention: LMA Gastro (n=26): 76.9231 (10.0833); Standard of Care (n=30): 77.7 (15.0611). End tidal carbon dioxide [CO2] prior to intervention: LMA Gastro (n=26): 18.6364 (11.4129); Standard of Care (n=30): 25.2 (11.7858). End tidal carbon dioxide [CO2] post intervention: LMA Gastro (n=26): 22.0769 (9.1693); Standard of Care (n=30): 28.75 (10.707).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

To Describe Oxygen Saturations Within the Two Groups [From "anesthesia start" to "anesthesia end", on average 5 hours]. Mean, percentage of saturation (Standard Deviation). Oxygen saturation prior to intervention: LMA Gastro (n=26): 98.5769 (1.9426); Standard of Care (n=30): 99.033 (1.1885). Oxygen saturation post intervention: LMA Gastro (n=26): 93.7692 (1.6796); Standard of Care (n=30): 98.5 (1.9783).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

To Evaluate Anesthesiologist Placing the Device [At the end of procedure, between 5 - 10 minutes]. Number, percentage of successful attempts. Successful on Attempt 1: LMA Gastro (n=5): 77. Successful on Attempt 2: LMA Gastro (n=5): 19. Successful on Attempt 3: LMA Gastro (n=5): 4.